To evaluate the overall diagnostic value of human epididymis protein 4 (HE4) combined with carbohydrate antigen 125 (CA125) in endometrial carcinoma (EC) based on a meta-analysis of all eligible studies. The PubMed, Cochrane, Embase, CNKI, VANFUN, and VIP databases were searched by index words to identify eligible studies and also to search for relevant literature sources that had been published by January 2019. Eligible studies included prospective cohort studies or cross-sectional studies. The heterogeneity of the included studies was used to select appropriate effect models to calculate summary weighted sensitivity, specificity, and diagnostic odds ratios (DORs). The summary receiver operational characteristic (SROC) analysis was summarized for the EC. In total, 25 studies that had explored the diagnostic accuracy of HE4 combined with CA125 for EC were included in this meta-analysis. Nine were from English language articles and 16 from Chinese language articles. The global sensitivity and specificity of HE4 combined with CA125 for EC were as follows: 66% (95% CI: 60-72) and 92% (95% CI: 88-95), respectively. The global positive likelihood ratio and global negative likelihood ratio of HE4 combined with CA125 for EC were as follows: 8.03 (95% CI: 5.36-12.04) and 0.37 (95% CI: 0.31-0.44), respectively. The global DOR was19.59 (95% CI: 12.25-31.32) for IL-6. The area under the SROC was high for HE4 combined with CA125 (AUC = 0.86; 95% CI: 0.83-0.89). This study provides a systematic review and meta-analysis of the diagnostic accuracy of HE4 combined with CA125 for EC. The results indicate that HE4 combined with CA125 is highly accurate for the diagnosis of EC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/gtmb.2019.0046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Multimodal Model Based on Transvaginal Ultrasound-Based Radiomics to Predict the Risk of Peritoneal Metastasis in Ovarian Cancer: A Multicenter Study.
Acad Radiol
January 2025
Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China (Y.Z., Y.D., Q.Z., C.Z.). Electronic address:
Rationale And Objectives: This study aimed to develop a predictive model for peritoneal metastasis (PM) in ovarian cancer using a combination radiomics and clinical biomarkers to improve diagnostic accuracy.
Patients And Methods: This retrospective cohort study of 619 ovarian cancer patients involved demographic data, radiomics, O-RADS standardized description, clinical biomarkers, and histological findings. Radiomics features were extracted using 3D Slicer and Pyradiomics, with selective feature extraction using Least Absolute Shrinkage and Selection Operator regression.
Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma.
Cancers (Basel)
November 2024
Department of Population Medicine and Lifestyle Diseases Prevention, The Faculty of Medicine, Medical University of Białystok, 15-269 Białystok, Poland.
Background: Ovarian carcinoma (OC) has an unfavorable prognosis due to lack of screening and an asymptomatic course. New diagnostic methods are being sought to enable earlier diagnosis of this condition. The purpose of this study was to determine the diagnostic utility of collagenases (MMP-1, MMP-8 and MMP-13) in the diagnosis of OC compared to HE4 and CA125 and the ROMA.
View Article and Find Full Text PDFValue of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancer.
Mol Biol Rep
December 2024
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Objective: This study aimed to analyse the diagnostic performance of miR200b in epithelial ovarian cancer (EOC) in a group of Egyptian patients and to evaluate the combined use of miR200b with other biomarkers as a reliable diagnostic and prognostic indicator of EOC.
Methods: We tested the expression of cell-free miR200b in 30 EOC patients before undergoing optimum cytoreductive surgery, 19 females with benign ovarian disease and 14 normal healthy females using quantitative real time PCR. All cases were tested for CA125, HE4 and CRP.
Predictive Role of HE4 in Diagnosis of Ovarian Tumors.
J Obstet Gynaecol India
October 2024
Obstretrics and Gynecology, IGIMS, Patna, India.
Background: Approximately 20% of women develop an ovarian cyst or pelvic mass at some point in their lives. Due to high false positivity of CA-125, women with various benign ovarian tumors simulating malignant masses undergo extensive debulking surgery resulting in increased morbidity. Serum HE4 is a useful test for better discrimination of benign or malignant nature of pelvic masses in preoperative period.
View Article and Find Full Text PDFDiagnostic accuracy of ultrasound classifications - O-RADS US v2022, O-RADS US v2020, and IOTA SR - in distinguishing benign and malignant adnexal masses: Enhanced by combining O-RADS US v2022 with tumor marker HE4.
Eur J Radiol
December 2024
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Ultrasound, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. Electronic address:
Article Synopsis
- The study aimed to evaluate the diagnostic accuracy of O-RADS Ultrasound versions 2022 and 2020, as well as the IOTA SR, for identifying malignant adnexal masses in women.
- It included 613 women undergoing surgery, using histopathology as the reference for diagnosis, and employed statistical analyses to assess the test performances and inter-reviewer agreement.
- Results showed that O-RADS US v2022 performed similarly to v2020 while outperforming IOTA SR; also, combining O-RADS US v2022 with the tumor marker HE4 significantly improved diagnostic accuracy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!